Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity
or death, withdrawal of consent, lost to follow-up, or study termination from sponsor;
treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff
for final analysis.
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
Active, not recruiting
The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111
plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory
non-Hodgkin follicular lymphoma.
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab
versus bendamustine plus rituximab in previously untreated participants with mantle cell
lymphoma (MCL) who are not eligible for stem cell transplantation.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.